To reduce unacceptably high death rates from snakebite envenomation, sub-Saharan Africa must adopt not only a new generation of multivalent biotech antivenoms, but also an infrastructure to deliver them.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Shortcomings in snake bite management in rural Cameroon: a case report
BMC Research Notes Open Access 08 June 2017
-
Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG
Scientific Reports Open Access 03 February 2017
-
Retrospective study on the incidence of envenomation and accessibility to antivenom in Burkina Faso
Journal of Venomous Animals and Toxins including Tropical Diseases Open Access 16 March 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Chippaux, J-P. Venins de Serpent et Envenimations (IRD Editions, Col. Didactiques, Paris, 2002).
Gutiérrez, J.M., Theakston, R.D.G. & Warrell, D.A. PLoS Med. 3, 727–731 (2006)
Chippaux, J-P. Toxicon 36, 1503–1506 (1998).
Chippaux, J-P. in Perspectives in Molecular Toxinology (ed. Ménez, A.) 457–472 (Wiley & Sons, London, 2002).
Lalloo, D.G. & Theakston, R.D.G. J. Toxicol. Clin. Toxicol. 41, 277–290 (2003).
Chippaux, J.P. Bull. Soc. Pathol. Exot. 98, 263–268 (2005).
Theakston, R.D.G., Warrell, D.A. & Griffiths, E. Toxicon 41, 541–557 (2003).
Chippaux, J.P., Stock, R.P. & Alagón, A. Toxicon 46, 115–118 (2005).
Chippaux, J.P., Lang, J., Amadi-Eddine, S., Fagot, P. & Le Mener, V. Am. J. Trop. Med. Hyg. 61, 1017–1018 (1999).
Nkinin, S.W. et al. Bull. Soc. Pathol. Exot. 90, 277–281 (1997).
Acknowledgements
Many people have contributed to this initiative and continue to do so. From the Republic of Benin, we wish to warmly acknowledge the absolutely essential work of all the health personnel involved in the ongoing clinical trials. From the Instituto Bioclon (Mexico City), the makers of Africamyn, for their consistent support in every imaginable way: J. López de Silanes, J. Paniagua-Solís, J. Estévez and others; from the Instituto de Biotecnología, B. Ramos-Cerrillo and Adolfo de Roodt. From Latoxan (France), Y. Doljansky and F. Principaud. And to all the participants at the 2ème Colloque sur les envenimations en Afrique, Cotonou, 2004, who have contributed, and continue to contribute, invaluable epidemiological data for quite a few West and Central African countries.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
We have a research grant from Instituto Biolclon, S.A. de C.V. (a Mexican producer of antivenoms for developing snake antivenom to be used in Africa. R.P.S. and A.A. also receive consultation fees from Bioclon.
Rights and permissions
About this article
Cite this article
Stock, R., Massougbodji, A., Alagón, A. et al. Bringing antivenoms to Sub-Saharan Africa. Nat Biotechnol 25, 173–177 (2007). https://doi.org/10.1038/nbt0207-173
Issue Date:
DOI: https://doi.org/10.1038/nbt0207-173
This article is cited by
-
Shortcomings in snake bite management in rural Cameroon: a case report
BMC Research Notes (2017)
-
Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG
Scientific Reports (2017)
-
Retrospective study on the incidence of envenomation and accessibility to antivenom in Burkina Faso
Journal of Venomous Animals and Toxins including Tropical Diseases (2016)
-
Mapping current and future potential snakebite risk in the new world
Climatic Change (2016)
-
Use of antivenoms for the treatment of envenomation by Elapidae snakes in Guinea, Sub-Saharan Africa
Journal of Venomous Animals and Toxins including Tropical Diseases (2013)
